INVESTOR RELATIONS
OVERVIEW
Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs. Amarin's development pipeline includes a program in Huntington's disease and Myasthenia Gravis, two programs in Parkinson's disease, one in epilepsy, one in memory and a series of programs in cardiovascular disease.
Market Listings For Amarin Stock
Amarin is listed on the Nasdaq capital market (ticker: AMRN).
INVESTOR RELATIONS
Recent News
more >>
| 31-Jul-2008 | Amarin Announces Annual General Meeting Concluded |
| 22-Jul-2008 | Amarin Proceeding to Phase 3 with AMR101 for Hypertriglyceridemia |
| 8-Jul-2008 | Amarin Notice of Annual General Meeting |
INVESTOR RELATIONS
Investor Relations Contacts
|
Amarin Corporation plc |
Company Registrars
| Lloyds TSB Registrars, The Causeway, Worthing, West Sussex BN99 6DA, UK |
Citi, |
This page was last updated on July, 1 2008.
